As it preps Phase III kidney trial on its own, AM-Pharma raises €116M series C

How AM-Pharma turned to European venture investors to fund a Phase III study of recAP to treat acute kidney injury

After Pfizer declined to exercise its option to acquire AM-Pharma, the Dutch biotech has turned to European venture investors for a €116 million ($131 million) series C round to fund a Phase III study of recAP to treat acute kidney injury.

CEO

Read the full 416 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE